AndhraNews.net
Home » Business News » 2014 » June » June 26, 2014

Perma-Fix to Present at NNSA's 2014 Mo-99 Conference


June 26, 2014 - Atlanta, Ga And Warsaw, Poland

ATLANTA, GA and WARSAW, POLAND--(Marketwired - June 26, 2014) - Perma-Fix Medical, a subsidiary of Perma-Fix Environmental Services, Inc., (NASDAQ: PESI), developer of a reliable, cost effective, non-uranium process to produce technetium-99 (Tc-99m), the most widely used medical isotope in the world, today announced that Dr. Louis F. Centofanti will be presenting "A Novel Micro-Porous Sorbent for Mo-99/Tc-99m Generator Using (n.g) Mo-99" at the National Nuclear Security Administration's (NNSA) 2014 Mo-99 Topical Meeting on June 27, 2014.

NNSA's 2014 Mo-99 Topical Meeting is hosted by Argonne National Laboratory, and will take place in Washington D.C. from June 24-27, 2014. This meeting is intended to serve as a workshop where international and domestic policy and technical experts can gather to present and discuss progress toward achieving the production of Mo-99 without the use of HEU in support of nonproliferation objectives and global reliability of supply.

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services, a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages and reliability issues of Tc-99m as it is cost competitive, simple, does not require the use of uranium as a starting material, and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at http://www.medical-isotope.com.

Contacts:
David K. Waldman
US Investor Relations
Crescendo Communications, LLC
(212) 671-1021

Herbert Strauss
European Investor Relations
herbert@eu-ir.com
+43 316 296 316

MarketWire

Comment on this story

Share